Search

20 F 2020

Media

https://www.gsk.com/media/7971/20-f-2020.pdf

First published: 01 June 2022

20 F 2019

Media

https://www.gsk.com/media/7981/20-f-2019.pdf

First published: 01 June 2022

2024 Annual Report on Form 20-F

Media

https://www.gsk.com/media/11872/2024-annual-report-on-form-20-f.pdf

First published: 03 March 2025

ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1

Media

ViiV Healthcare present their three-year results from the phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-dolutegravir-plus-lamivudine-three-year-data-confirming-long-term-viral-suppression/

First published: 05 October 2020

ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021

Media

ViiV Healthcare announce the presentation of 13 abstracts from its portfolio of pipeline prevention options.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-key-data-that-provides-further-support-for-the-use-of-2-drug-regimens/

First published: 22 September 2021

ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023

Media

Other key data to be presented include new HIV prevention findings for long-acting cabotegravir  and predictors of response to N6LS

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-first-head-to-head-data-for-long-acting-hiv-treatment-cabenuva-against-daily-oral-biktarvy-at-croi-2023/

First published: 14 February 2023

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

Media

ViiV Healthcare to present new long-term findings at CROI 2022

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-long-term-findings-from-its-innovative-2-drug-and-long-acting-hiv-medicines-portfolio-at-croi-2022/

First published: 07 February 2022

IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

Media

Presentations include six-year data for the investigational regimen of cabotegravir and rilpivirine.

https://www.gsk.com/en-gb/media/press-releases/idweek-2019-viiv-healthcare-to-present-20-abstracts-from-its-innovative-rd-portfolio-with-focus-on-2-drug-and-long-acting-regimens-and-mental-health-impact-of-hiv/

First published: 02 October 2019

ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022

Media

Data to be presented include long-term and real-world data from portfolio of medicines

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-from-innovative-hiv-treatment-and-prevention-portfolio-at-aids-2022/

First published: 25 July 2022

IAS 2019: ViiV Healthcare showcasing innovation in HIV science

Media

challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living with HIV

https://www.gsk.com/en-gb/media/press-releases/ias-2019-viiv-healthcare-showcasing-innovation-in-hiv-science/

First published: 15 July 2019